UniQure BV of the Netherlands, whose gene therapy was the first to receive approval by a western regulatory authority, has appointed Philip Astley-Sparke as president of its US operations. Mr Astley-Sparke will help build the company’s clinical, regulatory and commercial infrastructure in the US. He is currently a venture partner at Forbion Capital Partners, UniQure’s largest investor. He is the former president and chief executive of BioVex Inc, a Forbion investment, that was acquired by Amgen Inc in 2011. Mr Astley-Sparke is a qualified chartered accountant and holds a bachelor’s degree in cellular pathology and molecular pathology from Bristol University in the UK.
UniQure announced the appointment on 22 January 2013.
Copyright 2013 Evernow Publishing Ltd.